<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Recurrent aphthous stomatitis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Recurrent aphthous stomatitis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Recurrent aphthous stomatitis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sylvia Brice, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Giovanni Lodi, DDS, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert P Dellavalle, MD, PhD, MSPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rosamaria Corona, MD, DSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 18, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1250542269"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Recurrent aphthous stomatitis (RAS), also known as "canker sores," is a common disease of unknown etiology that affects the oral mucosa and is characterized by the repeated development of one to many discrete, painful ulcers that usually heal within 7 to 14 days [<a href="#rid1">1-6</a>]. The lesions are typically 3 to 5 mm, round to oval ulcers with a peripheral rim of erythema and a yellowish, adherent exudate centrally. The frequency of ulcer development is highly variable, with some patients noting only an occasional lesion and others experiencing such recurrent episodes that they almost have continuous ulcer activity [<a href="#rid1">1-6</a>].</p><p>This topic will discuss the pathogenesis, clinical manifestations, and management of RAS. Other causes of oral and genital ulceration are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5572.html" rel="external">"Oral lesions"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/8223.html" rel="external">"Clinical manifestations and diagnosis of Behçet syndrome"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7592.html" rel="external">"Approach to the patient with genital ulcers"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/94795.html" rel="external">"Acute genital ulceration (Lipschütz ulcer)"</a>.)</p><p></p><p class="headingAnchor" id="H198913516"><span class="h1">CLINICAL SUBTYPES</span><span class="headingEndMark"> — </span>Clinical subtypes of RAS include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Minor aphthous stomatitis</strong> – Minor aphthous stomatitis represents the most common form [<a href="#rid7">7</a>]. The ulcers are shallow, &lt;1 cm in diameter, can be single or multiple, and have a typical round shape. They are often painful, last 5 to 10 days, and heal without scarring. Most patients report a few episodes in one year.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Major aphthous stomatitis</strong> – Major aphthous stomatitis is a less common form. Lesions are larger (usually &gt;1 cm in diameter), deep, extremely painful, and last for weeks or months. In some cases, major aphthae may be misdiagnosed as a vesiculobullous disorder, squamous cell carcinoma, or granulomatous disease. The lesions may heal with scar formation. In patients with human immunodeficiency virus (HIV), recurrent aphthous ulcers are often &gt;1 cm in diameter.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Herpetiform aphthous stomatitis</strong> – Herpetiform aphthous stomatitis is a rare variant characterized by multiple ulcers, similar to those of the minor form but much smaller (measuring a few millimeters), that also heal within 7 to 10 days. They resemble herpes simplex virus-related ulcers.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severe aphthous stomatitis</strong> – Patients with this RAS variant are almost never ulcer free. They typically develop new ulcers when the previous ones are healing and often present with chronic pain, malnutrition, and weight loss. Both the keratinized and nonkeratinized mucosa may be affected.</p><p></p><p class="headingAnchor" id="H3216840646"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>RAS is seen throughout the world, with the greatest prevalence in the Middle East, the Mediterranean region, and South Asia [<a href="#rid6">6,8</a>]. In North America, it occurs approximately in one out of five individuals and is the most common cause of acute recurrent oral ulcers. Most individuals first develop RAS during adolescence, although it is not uncommonly seen in children. The disease may continue into adulthood but typically wanes with increasing age. It is unusual for patients over the age of 40 to develop new-onset RAS.</p><p class="headingAnchor" id="H554514172"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The pathogenesis of RAS is unknown and is likely multifactorial [<a href="#rid1">1-6</a>]. Most investigations have supported the concept of immune dysregulation involving T cells and tumor necrosis factor (TNF)-alpha leading to an exaggerated, proinflammatory process or a relatively weak, anti-inflammatory response [<a href="#rid9">9-16</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic susceptibility</strong> – There appears to be a genetic predisposition to developing RAS, as it is common for patients to have a family history of RAS. Several specific human leukocyte antigens (HLAs) have been associated with RAS (HLA-A2, HLA-B5, HLA-B12, HLA-B44, HLA-B51, HLA-B52, HLA-DR2, HLA-DR7, and HLA-DQ), supporting the inherited nature of this disease [<a href="#rid17">17</a>]. In a systematic review and meta-analysis of 23 studies, polymorphisms of serotonin transporter (L/S), interleukin (IL) 10-819 (T/C), IL-10-592 (C/A), IL-10-1082 (G/A), IL-1-beta-511 (C/T), IL-6-174 (G/C), and IL-1-beta+3954 (T/C) were associated with susceptibility to RAS [<a href="#rid18">18</a>]. In another study that included 60 patients with RAS and 40 age- and sex-matched controls without RAS, gene polymorphisms for cytokines IL-10 at loci -592 and -819 and gene polymorphisms for transforming growth factor (TGF)-beta-1 at codon 10 were detected more frequently in patients with RAS [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Microbiota alterations</strong> – Studies examining the oral flora diversity in patients with RAS compared with controls without RAS provided conflicting results, with some reporting reduced normal commensal flora and increased prevalence of uncommon species (eg, <em>Prevotella</em>, <em>Bacteroides</em>) [<a href="#rid20">20-23</a>] The role of viral infections (eg, <em>Cytomegalovirus</em>, varicella zoster virus, and human herpes virus) remains uncertain.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other factors</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Micronutrient deficiency</strong> – Vitamin and mineral deficiencies (in particular, <a class="drug drug_general" data-topicid="9302" href="/z/d/drug information/9302.html" rel="external">vitamin B12</a>, vitamin D, iron, folate, and zinc) have been implicated in the pathogenesis of RAS, although the role of vitamin supplementation in the treatment of RAS remains uncertain and reserved to patients with documented deficiencies [<a href="#rid24">24,25</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Food allergy</strong> –<strong> </strong>Although certain foods may exacerbate RAS, and some studies have reported sensitivity to foods, preservatives, or other agents in 35 to 50 percent of patients with a diagnosis of RAS [<a href="#rid26">26</a>], there is no evidence to suggest an etiologic role for food allergy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Drugs</strong> – Certain drugs (eg, beta blockers, <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, nicorandil) have been documented to induce oral ulcers similar to aphthous ulcers [<a href="#rid27">27,28</a>]. The ulcers typically resolve when the drug is discontinued.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Smoking</strong> – Although a few observational studies reported a temporary increase of RAS in the first few weeks after smoking cessation, other studies have not found any relationship between RAS and smoking [<a href="#rid8">8,29-31</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Stress</strong> – Emotional stress may lead to an exacerbation of disease [<a href="#rid32">32</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Triggers</strong> – Many patients with RAS experience an exacerbation of their disease following trauma to the oral mucosa, such as biting the inside of the cheek or undergoing a dental procedure. In these patients, one or more ulcers will predictably develop in the area of trauma over the next couple of days [<a href="#rid11">11,33</a>]. Other possible precipitating factors include psychologic stress, anxiety, hormonal fluctuations, certain foods, and sodium lauryl sulfate-containing toothpaste.</p><p></p><p class="headingAnchor" id="H3152628500"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Age of onset</strong> – Most patients with RAS first experience oral ulcers during adolescence and early adulthood. They may develop one to several lesions, which are self-limited in nature, at a time. Patients may continue to develop lesions through middle age, but the frequency typically diminishes over time.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Morphology</strong> – Lesions of RAS have a very characteristic appearance [<a href="#rid1">1-6</a>]. They are discrete; round or oval; with an erythematous rim and adherent, yellowish exudate centrally  (<a class="graphic graphic_picture graphicRef63475 graphicRef114283 graphicRef114284" href="/z/d/graphic/63475.html" rel="external">picture 1A-C</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Number and size of lesions </strong>–<strong> </strong>Patients with minor aphthosis typically have one to five discrete ulcers limited to the oral mucosa that are &lt;1 cm in diameter [<a href="#rid4">4</a>]. However, in patients with the major form, ulcers are &gt;1 cm. The herpetiform variant is characterized by small ulcers (1 to 3 mm in diameter), often occurring in clusters. (See <a class="local">'Clinical subtypes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Location </strong>– The oral lesions of RAS most commonly develop on the nonkeratinized oral mucosa, typically buccal and labial mucosae. The gingival sulci, lateral and ventral tongue, soft palate, and anterior pharynx may also be involved. The involvement of the keratinized mucosae, such as hard palate and attached gingivae, is much less common.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Time course of progression</strong> – A lesion typically progresses from a painful, pinpoint papule into an ulcer over a period of one to two days; patients are often able to identify lesions in this early stage and initiate treatment promptly. The ulcer gradually expands to its final size over the next three to four days and then stabilizes before beginning to heal. In some patients, lesions may come and go within four to five days, but in most individuals, they resolve in 10 to 14 days. Major ulcers may take four to eight weeks to resolve.</p><p></p><p class="bulletIndent1">Most patients will go for weeks to months between episodes. However, some patients may report such frequent episodes that they almost always have at least one ulcer present. (See <a class="local">'Management'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pain and systemic symptoms</strong> – The ulcers may be very painful and, in some cases, may interfere with the ability to eat, drink, and talk. Although patients may be very uncomfortable, only a few experience systemic symptoms or signs associated with outbreaks of their aphthous ulcers.</p><p></p><p class="headingAnchor" id="H3682988628"><span class="h1">EVALUATION AND DIAGNOSIS</span></p><p class="headingAnchor" id="H3017255661"><span class="h2">Clinical diagnostic criteria</span><span class="headingEndMark"> — </span>The diagnosis of RAS is typically made clinically, based on patient history and physical examination. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Key elements in the diagnosis of <strong>minor </strong>RAS include [<a href="#rid1">1-6</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>History of recurrent, self-limited, painful ulcers of the oral mucosa that heal within two weeks without scarring</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Discrete, shallow, round to oval ulcers, usually &lt;1 cm in diameter, with an erythematous rim and yellowish exudate  (<a class="graphic graphic_picture graphicRef63475 graphicRef114283 graphicRef114284" href="/z/d/graphic/63475.html" rel="external">picture 1A-C</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Absence of systemic symptoms (eg, fever, malaise, myalgias, cervical lymphadenopathy)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Elements that suggest the diagnosis of <strong>major</strong> RAS include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>History of recurrent, extremely painful ulcers of the oral mucosa that last for weeks or months and may heal with scarring</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Discrete, deep ulcers, usually &gt;1 cm in diameter</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Systemic symptoms generally absent</p><p></p><p>However, additional evaluation is required for patients presenting with systemic symptoms/comorbidities to exclude other conditions associated with oral ulcerations. (See <a class="local">'Differential diagnosis'</a> below.)</p><p class="headingAnchor" id="H498477400"><span class="h2">Patient evaluation</span></p><p class="headingAnchor" id="H18679463"><span class="h3">Patient history</span><span class="headingEndMark"> — </span>A history of recurrent, self-limited oral lesions that demonstrate the characteristic appearance of discrete, round or oval ulcers with an erythematous rim and yellowish exudate and persist for several days to up to several weeks is characteristic of RAS. The history of developing an ulcer at a site of trauma is very common in patients with RAS.</p><p>Below is a list of suggested questions for patients with oral ulcers:</p><p class="bulletIndent1"><span class="glyph">●</span>When did the condition start or get worse?</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>What is the natural history of the lesions? Do they come and go? Come and persist?</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Does trauma tend to precipitate a new lesion?</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Are the lesions symptomatic?</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Is there a history of skin disease involving other body sites? Specifically ask about the anogenital region.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Does the patient have any symptoms suggestive of other sites of mucosal involvement (eg, dysphagia, hoarseness, stridor, ocular irritation, dysuria, dyspareunia, hematuria)?</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Does the patient have other medical conditions, including immunosuppression?</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Does the review of systems suggest any underlying disease?</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Is the patient currently taking any suspect medications?</p><p></p><p class="headingAnchor" id="H2387590008"><span class="h3">Physical examination</span><span class="headingEndMark"> — </span>Aphthous ulcers have a very characteristic appearance. The ulcers are discrete and usually 3 to 5 mm in diameter  (<a class="graphic graphic_picture graphicRef63475 graphicRef114283 graphicRef114284" href="/z/d/graphic/63475.html" rel="external">picture 1A-C</a>). They have an erythematous halo at the margin and a yellowish exudate centrally. They may be found throughout the oral mucosa but are especially common on the buccal and labial mucosae and the lateral and ventral tongue. (See <a class="local">'Clinical manifestations'</a> above.)</p><p>When evaluating the patient with oral ulcers, a physical examination of all mucocutaneous surfaces, including the scalp, nails, and anogenital region, may be useful to exclude other underlying skin disease, such as autoimmune bullous diseases or lichen planus.</p><p class="headingAnchor" id="H1417519820"><span class="h3">Biopsy</span><span class="headingEndMark"> — </span>The diagnosis of RAS is typically made clinically. However, in more severe or atypical presentations, a biopsy may be useful to rule out other mucosal disease.</p><p>A biopsy at the periphery of an early, ulcerative lesion is the most useful. If the disease is extensive enough to mimic an autoimmune bullous disease (eg, pemphigus vulgaris or cicatricial pemphigoid), performing a biopsy for direct immunofluorescence examination may be helpful. (See  <a class="medical medical_review" href="/z/d/html/5577.html" rel="external">"Skin biopsy techniques"</a> and  <a class="medical medical_review" href="/z/d/html/83684.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of pemphigus", section on 'Diagnosis'</a>.)</p><p>Histopathology of an active ulcer shows epithelial necrosis and a neutrophilic infiltrate centrally. At the periphery, the infiltrate is predominantly lymphocytic with some exocytosis and epithelial degeneration [<a href="#rid34">34</a>]. Direct immunofluorescence is nonspecific, with possible deposition of C3 or immunoglobulin M (IgM) in blood vessels.</p><p class="headingAnchor" id="H3182456825"><span class="h3">Laboratory tests</span><span class="headingEndMark"> — </span>For most patients with minor aphthosis, no laboratory assessment is needed. For patients with more severe or worsening disease or those who develop the process later in life, it is reasonable to search for an underlying cause. A complete blood count, erythrocyte sedimentation rate, C-reactive protein, and assessment of nutritional deficiencies (eg, <a class="drug drug_general" data-topicid="9302" href="/z/d/drug information/9302.html" rel="external">vitamin B12</a>, folate, iron, vitamin D) may reveal a disorder that, when corrected, could potentially lead to resolution or improvement of the ulcers [<a href="#rid35">35-37</a>]. Additional laboratory assessment may be considered in individuals with signs or symptoms suggesting an underlying or associated systemic disease. (See <a class="local">'Differential diagnosis'</a> below.)</p><p class="headingAnchor" id="H238686915"><span class="h1">DIFFERENTIAL DIAGNOSIS</span></p><p class="headingAnchor" id="H1805965673"><span class="h2">Mucocutaneous diseases associated with oral ulcers</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Herpes simplex virus infection </strong>– Primary herpetic gingivostomatitis may present with extensive oral and pharyngeal ulcerations. Fever, malaise, myalgias, and cervical lymphadenopathy are common accompanying symptoms. Recurrent oral-labial herpes simplex virus type 1 infections (also called herpes labialis, "cold sores," or "fever blisters") usually involve the cutaneous lip and infrequently develop within the oral cavity  (<a class="graphic graphic_picture graphicRef117246" href="/z/d/graphic/117246.html" rel="external">picture 2</a>). When this does occur, lesions typically develop on the hard palate or gingival mucosa, in contrast with RAS, which involves the buccal and labial mucosa, ventral tongue, and soft palate in most cases. Recurrent intraoral herpes simplex virus may also raise suspicion for underlying immunosuppression [<a href="#rid38">38</a>]. Viral culture or polymerase chain reaction can confirm the diagnosis. (See  <a class="medical medical_review" href="/z/d/html/8334.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of herpes simplex virus type 1 infection", section on 'Oral infections'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral erosive lichen planus</strong> – The oral lesions of major aphthosis may heal with scarring that resembles the white, reticular network seen in oral erosive lichen planus. However, in oral lichen planus, the lesions tend to be more limited in distribution and more chronic in nature. The more characteristic discrete, circular ulcers of RAS are not seen. (See  <a class="medical medical_review" href="/z/d/html/15285.html" rel="external">"Oral lichen planus: Pathogenesis, clinical features, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Autoimmune bullous disease</strong> – The mucosal lesions of major aphthosis can sometimes be extensive enough that this process may be confused with an autoimmune bullous dermatosis (eg, pemphigus vulgaris or cicatricial pemphigoid). However, even in severe major aphthosis, there is usually an episodic nature to the disease, as opposed to the chronicity seen in pemphigus or pemphigoid. These entities may be distinguished from RAS by biopsy, including direct immunofluorescence. (See  <a class="medical medical_review" href="/z/d/html/83684.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of pemphigus"</a> and  <a class="medical medical_review" href="/z/d/html/16176.html" rel="external">"Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug-induced mucosal ulcers</strong> – Nicorandil, used for treating angina, has been reported to induce aphthous-like ulcers. This drug is not available in the United States. Nonsteroidal anti-inflammatory drugs (NSAIDs) have also been implicated in the development of aphthous stomatitis. (See  <a class="medical medical_review" href="/z/d/html/5572.html" rel="external">"Oral lesions", section on 'Nicorandil-induced ulceration'</a>.)</p><p></p><p class="headingAnchor" id="H122509265"><span class="h2">Systemic diseases associated with oral ulcers</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Behçet syndrome</strong> – Behçet syndrome is a rare disease characterized by recurrent oral aphthae and any of several systemic manifestations, including genital aphthae, ocular disease, skin lesions, gastrointestinal disease, neurologic disease, vascular disease, and arthritis [<a href="#rid39">39</a>]. The diagnosis is based on the presence of recurrent oral ulcerations plus at least two additional findings, including recurrent genital ulcerations, eye lesions, skin lesions, and positive pathergy test  (<a class="graphic graphic_table graphicRef54762" href="/z/d/graphic/54762.html" rel="external">table 1</a>). Oral ulcers, clinically and histologically indistinguishable from common aphthae, are the most common feature (affecting 92 to 100 percent of patients), followed by genital ulcers (57 to 93 percent) and cutaneous lesions (38 to 99 percent) [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent1">Caution should be used in making the diagnosis of Behçet syndrome in patients with aphthosis, especially in patients who are not from areas where this disease is more prevalent (eg, the Silk Road, from Japan to the Middle East and Mediterranean countries). In a United States study of 64 patients with major aphthosis, only 10 (16 percent) met the diagnostic criteria for Behçet syndrome [<a href="#rid41">41</a>]. (See  <a class="medical medical_review" href="/z/d/html/8223.html" rel="external">"Clinical manifestations and diagnosis of Behçet syndrome"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Systemic lupus erythematosus</strong> – Oral or nasopharyngeal ulcers satisfy one criterion for the diagnosis of systemic lupus erythematosus  (<a class="graphic graphic_picture graphicRef63605" href="/z/d/graphic/63605.html" rel="external">picture 3</a>). Biopsy shows a lichenoid pattern of inflammation, which differs from typical RAS [<a href="#rid42">42</a>]. In addition, photosensitivity, malar rash, arthritis, and other systemic involvement would be anticipated in patients with systemic lupus erythematosus. (See  <a class="medical medical_review" href="/z/d/html/4666.html" rel="external">"Overview of cutaneous lupus erythematosus", section on 'Mucosal manifestations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cyclic neutropenia</strong> – Cyclic neutropenia is a rare autosomal dominant disorder of bone marrow progenitor cells characterized by the cyclic occurrence of fever, malaise, pharyngitis, aphthous-like ulcers, and neutropenia beginning during infancy or early childhood. Neither the predictability nor the systemic symptoms are seen in typical RAS [<a href="#rid43">43</a>]. (See  <a class="medical medical_review" href="/z/d/html/8370.html" rel="external">"Cyclic neutropenia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>PFAPA syndrome</strong> – PFAPA (<strong>p</strong>eriodic <strong>f</strong>ever with <strong>a</strong>phthous stomatitis, <strong>p</strong>haryngitis, and <strong>a</strong>denitis) syndrome is the most common periodic fever syndrome in children. Like cyclic neutropenia, PFAPA syndrome tends to follow a pattern of recurrence approximately once a month. However, there is no associated neutropenia [<a href="#rid44">44</a>]. (See  <a class="medical medical_review" href="/z/d/html/5953.html" rel="external">"Periodic fever with aphthous stomatitis, pharyngitis, and adenitis (PFAPA syndrome)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>MAGIC syndrome</strong> – MAGIC (<strong>m</strong>outh <strong>a</strong>nd <strong>g</strong>enital ulcers with <strong>i</strong>nflamed <strong>c</strong>artilage) syndrome represents an overlap syndrome of relapsing polychondritis and Behçet syndrome [<a href="#rid45">45</a>]. Associated findings may include aortitis and thoracic aortic aneurysm [<a href="#rid46">46-48</a>]. (See  <a class="medical medical_review" href="/z/d/html/5606.html" rel="external">"Clinical manifestations of relapsing polychondritis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Celiac disease</strong> – There is evidence of an association between celiac disease and aphthous stomatitis [<a href="#rid49">49-51</a>]. In patients presenting with RAS, it is reasonable to inquire about a history of gastrointestinal complaints or known gluten intolerance. The prevalence of aphthous stomatitis in patients with celiac disease ranges from 3 to 61 percent [<a href="#rid35">35</a>]. Dental enamel defects are also common oral manifestations of celiac disease. Antitissue transglutaminase immunoglobulin A antibody (tTG-IgA) and antiendomysial immunoglobulin A antibody (EMA-IgA) should be performed in patients with recurrent aphthous lesions who also have gastrointestinal complaints and/or dental enamel defects to exclude or confirm a diagnosis of celiac disease. (See  <a class="medical medical_review" href="/z/d/html/5899.html" rel="external">"Epidemiology, pathogenesis, and clinical manifestations of celiac disease in children"</a> and  <a class="medical medical_review" href="/z/d/html/4774.html" rel="external">"Epidemiology, pathogenesis, and clinical manifestations of celiac disease in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inflammatory bowel disease</strong> – An association between inflammatory bowel disease and oral ulcers has been reported [<a href="#rid52">52</a>]. In Crohn disease, the ulcerations may have a characteristic linear shape  (<a class="graphic graphic_picture graphicRef138812" href="/z/d/graphic/138812.html" rel="external">picture 4</a>). Other oral features of Crohn disease may include cobblestoned buccal mucosa, angular cheilitis, and granular gingival swelling. In the patient presenting with RAS, it is reasonable to inquire about a history of gastrointestinal complaints [<a href="#rid53">53</a>]. (See  <a class="medical medical_review" href="/z/d/html/4067.html" rel="external">"Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/4070.html" rel="external">"Clinical manifestations, diagnosis, and prognosis of Crohn disease in adults"</a> and  <a class="medical medical_review" href="/z/d/html/5865.html" rel="external">"Clinical manifestations and complications of inflammatory bowel disease in children and adolescents"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>HIV infection</strong> – RAS, especially major aphthosis, can be a significant problem in patients with HIV infection. In general, major aphthosis has become less common in HIV-positive patients since the advent of successful antiretroviral therapy [<a href="#rid54">54-56</a>]. (See  <a class="medical medical_review" href="/z/d/html/3741.html" rel="external">"Initial evaluation of adults with HIV"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reactive arthritis</strong> – Oral lesions, including painless mucosal ulcers often located on the hard palate, can occur in patients with reactive arthritis (previously called Reiter syndrome)  (<a class="graphic graphic_picture graphicRef83797" href="/z/d/graphic/83797.html" rel="external">picture 5</a>). The diagnosis is usually clinical, based on the presence of arthritis and other extra-articular symptoms (eg, conjunctivitis, urethritis, keratoderma blennorrhagicum, circinate balanitis) in patients with a preceding or concurrent enteric or genitourinary infection. (See  <a class="medical medical_review" href="/z/d/html/7794.html" rel="external">"Reactive arthritis", section on 'Extraarticular signs and symptoms'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hyperimmunoglobulin D syndrome</strong> – Hyperimmunoglobulin D syndrome is a rare autosomal recessive genetic disorder characterized by recurrent, febrile episodes typically associated with lymphadenopathy, abdominal pain, and an elevated serum polyclonal immunoglobulin D level. Aphthous ulcers, and sometimes genital ulcers, are seen in approximately one-half of the patients with hyperimmunoglobulin D syndrome [<a href="#rid57">57</a>]. (See  <a class="medical medical_review" href="/z/d/html/5954.html" rel="external">"Hyperimmunoglobulin D syndrome: Clinical manifestations and diagnosis", section on 'Mucocutaneous manifestations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Agranulocytosis</strong> – Agranulocytosis is defined as having a neutrophil count &lt;500/mm<sup>3</sup> in the absence of anemia and thrombocytopenia. The vast majority of cases are drug induced. Agranulocytosis may be accompanied by oral ulcerations, fever, pharyngitis, dysphagia, and sepsis. (See  <a class="medical medical_review" href="/z/d/html/8374.html" rel="external">"Drug-induced neutropenia and agranulocytosis"</a>.)</p><p></p><p class="headingAnchor" id="H1041165521"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H3371401505"><span class="h2">Goals of therapy</span><span class="headingEndMark"> — </span>Treatment of aphthae is not always necessary, as the pain is often bearable and does not interfere with daily life activities. The goals of treatment, when indicated or requested by patients, are to provide relief from pain, speed up the healing of ulcers, decrease the frequency of episodes, and increase lesion-free periods. However, there is no uniformly effective therapy for RAS, and many topical or systemic agents have been used with variable success. Despite the common nature of this disorder, there is a paucity of high-quality studies evaluating treatments for RAS [<a href="#rid58">58-65</a>]. Management is based on limited evidence from low-quality, randomized trials and clinical experience [<a href="#rid35">35,59,66,67</a>].</p><p class="headingAnchor" id="H2068068876"><span class="h2">General measures for all patients</span><span class="headingEndMark"> — </span>General measures aimed at maintaining good oral hygiene, avoiding exacerbating factors, and reducing pain are appropriate for essentially all patients with RAS.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral hygiene</strong> – It is important to maintain good dental hygiene, while at the same time avoiding trauma. A soft toothbrush, waxed tape-style dental floss, and a soft-tipped gum stimulator to gently remove plaque are generally well tolerated. A non-alcohol-containing mouthwash is often less irritating, but still effective, in decreasing microbial overgrowth. Toothpaste containing sodium lauryl sulfate (SLS; also called sodium dodecyl sulfate) may exacerbate RAS in some patients. A trial of using SLS-free toothpaste could be considered [<a href="#rid68">68</a>].</p><p></p><p class="bulletIndent1">Regular, professional dental cleaning is advised.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Avoidance of exacerbating factors</strong> – Where possible, reduce traumatic factors inside the mouth (eg, sharp/rough dental restorations, braces). Avoid habits that cause trauma (eg, biting cheeks or lips) and foods that seem to exacerbate the process.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pain control</strong> – Topical anesthetics and coating agents can provide temporary relief of discomfort if used prior to eating and performing dental hygiene.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Viscous <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a> 2% or <a class="drug drug_general" data-topicid="9092" href="/z/d/drug information/9092.html" rel="external">benzocaine</a> 10% – Viscous lidocaine (available by prescription) may be applied directly to the surface of ulcers or used as a swish and spit.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">Diphenhydramine</a> liquid – 12.5 mg/5 mL; 5 mL swish and spit.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9397" href="/z/d/drug information/9397.html" rel="external">Dyclonine</a> lozenges – Dissolve slowly in mouth.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8499" href="/z/d/drug information/8499.html" rel="external">Aluminum hydroxide</a>, <a class="drug drug_general" data-topicid="9582" href="/z/d/drug information/9582.html" rel="external">magnesium hydroxide</a>, and <a class="drug drug_general" data-topicid="10264" href="/z/d/drug information/10264.html" rel="external">simethicone</a> suspension – 5 to 10 mL swish and spit.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Attapulgite suspension – 600 to 750 mg/15 mL; 5 to 10 mL swish and spit.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Control of secondary infection</strong> – Although topical antimicrobial therapy is generally not warranted in the routine management of patients with mild to moderate RAS, it may be helpful for some patients with extensive oral ulceration, especially if they are using topical or oral immunosuppressive agents. In this setting, topical therapies that are used to control overgrowth of <em>Candida</em> or bacteria include (see  <a class="medical medical_review" href="/z/d/html/2432.html" rel="external">"Oropharyngeal candidiasis in adults"</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9244" href="/z/d/drug information/9244.html" rel="external">Chlorhexidine</a> 1% gel applied directly to the ulcers or 0.12% mouth rinse (at a dose of 15 mL) swish and spit twice daily</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9287" href="/z/d/drug information/9287.html" rel="external">Clotrimazole</a> troches (at a dose of 10 mg) four to five times daily</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9712" href="/z/d/drug information/9712.html" rel="external">Nystatin</a> suspension (at a dose of 400,000 to 600,000 units) swish and swallow four times daily</p><p></p><p class="headingAnchor" id="H4009147883"><span class="h2">Initial therapy</span></p><p class="headingAnchor" id="H743303044"><span class="h3">Topical corticosteroids</span><span class="headingEndMark"> — </span>High-potency topical corticosteroids  (<a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">table 2</a>) are the first-line treatment for patients with RAS (including the major form). They are more effective if they are initiated early and used frequently for at least a few days. Ideally, the patient should have the medication readily available so it can be started at the first indication of an outbreak.</p><p><a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">Dexamethasone</a> elixir 0.5 mg/5 mL can be an excellent first choice. However, if this preparation is not available or has not been effective, medium- to high-potency topical corticosteroid preparations (eg, gel, ointment, paste) can be used.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">Dexamethasone</a> elixir 0.5 mg/5 mL – 5 mL swish and spit three to four times daily. It is important to keep the medication in the mouth for five minutes prior to spitting it out. Do not rinse afterward and avoid eating or drinking for 30 minutes.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9276" href="/z/d/drug information/9276.html" rel="external">Clobetasol</a><strong> </strong>0.05% gel or ointment – Apply a small amount to the area of involvement two to three times daily. This will work better if the mucosa is dried with a piece of gauze prior to the application of the medication. Do not rinse afterward and avoid eating or drinking for 30 minutes.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10015" href="/z/d/drug information/10015.html" rel="external">Triamcinolone</a><strong> </strong>acetonide 0.1% in Orabase – Orabase is a thick, paste-like material that may adhere better to isolated lesions but does not appeal to many patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – The efficacy of topical corticosteroids for the treatment of RAS was evaluated in a randomized trial including 240 patients with minor RAS treated with <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> ointment or placebo three times per day for five days [<a href="#rid69">69</a>]. Ulcer healing occurred in a higher proportion of patients in the dexamethasone ointment group than in the placebo group (88 versus 55 percent). Mild adverse effects occurred in 12 patients (4 in the treatment group and 8 in the control group) and included perioral rash, burning sensation in the larynx, and pain at the application site.</p><p></p><p class="bulletIndent1">In a 2011 systematic review of 43 randomized trials of topical and systemic therapies conducted in patients with RAS not associated with systemic diseases, a variety of topical (eg, topical corticosteroids, topical tetracyclines, amlexanox), systemic (systemic corticosteroids, <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a>) and destructive therapies (topical <a class="drug drug_general" data-topicid="9888" href="/z/d/drug information/9888.html" rel="external">silver nitrate</a>, laser therapy) were reported as effective in reducing pain and promoting ulcer healing [<a href="#rid35">35</a>].</p><p></p><p class="headingAnchor" id="H1915363778"><span class="h3">Other topical agents</span><span class="headingEndMark"> — </span>Other topical agents that can be used in combination or as an alternative to topical corticosteroids include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Topical tetracyclines</strong> – Topical <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a> and <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> (as mouth rinses, gels, or pastes) have been reported as effective in reducing pain or healing time of RAS in a few randomized trials [<a href="#rid70">70-72</a>]. These synthetic tetracyclines have multiple anti-inflammatory effects, including inhibition of collagenases and reduction of prostaglandin release. A pooled analysis of three small clinical trials found that a single application of topical doxycycline (a 100 mg tablet crushed and mixed with <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> and adhesive paste) was more effective than placebo in reducing the healing time (mean difference [days] -1.77, 95% CI -2.11 to -0.91) [<a href="#rid73">73</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sucralfate</strong><strong> suspension</strong> – <a class="drug drug_general" data-topicid="9953" href="/z/d/drug information/9953.html" rel="external">Sucralfate</a> is a sulfated polysaccharide complexed with <a class="drug drug_general" data-topicid="8499" href="/z/d/drug information/8499.html" rel="external">aluminum hydroxide</a> that can provide a protective barrier for mucosal ulceration. In three small randomized trials, sucralfate suspension (eg, 1 g in 10 mL) rinses four times/day was more effective than placebo in decreasing pain and duration of lesions in patients with RAS and in patients with oral and genital ulcers associated with Behçet syndrome [<a href="#rid74">74-76</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Topical hyaluronate</strong> – Topical <a class="drug drug_general" data-topicid="8643" href="/z/d/drug information/8643.html" rel="external">hyaluronic acid</a> (also known as hyaluronan) has been reported to provide pain relief and accelerated healing of RAS lesions. In a systematic review of nine clinical trials, the efficacy of topical hyaluronic acid in reducing pain and ulcer size was comparable with that of other interventions (topical corticosteroid, placebo, diode laser) [<a href="#rid77">77</a>]. The authors concluded that the evidence was inconclusive based on the heterogeneity of the included studies and high risk of bias in some of the studies. Hyaluronic acid is available without prescription as a 0.2% gel or mouth rinse.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Amlexanox</strong> – Amlexanox is a topical anti-inflammatory agent that has been evaluated for the treatment of RAS in a few small trials, although its precise mechanism of action is unknown.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In one study including 100 patients with simple RAS, amlexanox 5% paste applied to early lesions four times daily was more effective than placebo for reducing ulcer size and pain [<a href="#rid78">78</a>]. Mild adverse effects occurred in eight patients in the amlexanox group and included stinging or cooling sensation at the application site and metallic taste.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In another study including 96 patients with RAS, topical 5% amlexanox was as effective as 0.05% <a class="drug drug_general" data-topicid="9276" href="/z/d/drug information/9276.html" rel="external">clobetasol</a> propionate in reducing pain and ulcer size [<a href="#rid79">79</a>]. Amlexanox is no longer available in the United States.</p><p></p><p class="headingAnchor" id="H1616478953"><span class="h2">Refractory/major aphthosis</span></p><p class="headingAnchor" id="H1170057143"><span class="h3">Systemic corticosteroids</span><span class="headingEndMark"> — </span>For patients with RAS that does not respond to topical corticosteroids alone, we suggest a short course of systemic corticosteroids [<a href="#rid80">80</a>]. For most patients, the use of topical agents and intermittent use of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> (up to three times per year) is sufficient treatment.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – Oral <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 20 to 40 mg per day for four to seven days is the standard approach. In cases of major aphthosis, treatment can be prolonged until improvement of the ulcer and associated symptoms is noted and then tapered down. Systemic corticosteroids can be used intermittently (eg, up to three times per year) as an adjunctive treatment to topical therapies.</p><p></p><p class="bulletIndent1">In patients requiring more frequent or longer courses of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>, alternate systemic agents used on a chronic basis should be considered.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – The use of systemic corticosteroids is based on limited evidence from two small, low-quality randomized trials and clinical experience [<a href="#rid80">80,81</a>]. In one trial including 40 patients with severe RAS uncontrolled by topical corticosteroids, <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> (at a dose of 25 mg per day for two weeks and then tapered off in six weeks) was more effective than placebo in decreasing pain, time to ulcer healing, and number of new ulcers during treatment and at four months [<a href="#rid80">80</a>]. Treatment was generally well tolerated, but minor adverse events were more frequent in the prednisone group.</p><p></p><p class="headingAnchor" id="H2050023039"><span class="h3">Colchicine/dapsone</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">Colchicine</a> is an alternative treatment for RAS that is not controlled with intermittent use of systemic corticosteroids in adjunct to topical therapies. <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">Dapsone</a> can be added to that regimen if there is inadequate response to the colchicine alone or only a low dose of colchicine is tolerated.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Colchicine</strong> – The usual starting dose is 0.6 mg orally once daily. After one week, if tolerated, the dose is increased to 0.6 mg twice daily or 1.2 mg once daily. It can be further increased to 0.6 mg three times daily, but very few patients tolerate this dose without developing significant gastrointestinal complaints. In one study, gastrointestinal complications (17 percent), neutropenia (4 percent), and liver enzyme elevation (4 percent) occurred within two weeks of initiating treatment [<a href="#rid82">82</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Dapsone</strong> – The usual starting dose is 25 to 50 mg daily, which may be increased to a maximum of 150 mg daily, as tolerated. A baseline glucose-6-phosphate dehydrogenase (G6PD) level is recommended, and blood cell counts should be followed carefully, especially during the first three months of therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy </strong>– <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">Colchicine</a> has been used for the long-term treatment of major RAS and mucosal ulcers in Behçet syndrome with favorable results [<a href="#rid82">82-84</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a small randomized trial, <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a> showed efficacy in the treatment of mucosal ulcers in Behçet syndrome [<a href="#rid85">85</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a 12-month randomized trial, 106 adult patients with RAS were treated with <a class="drug drug_general" data-topicid="9139" href="/z/d/drug information/9139.html" rel="external">betamethasone</a> mouthwash (obtained by dissolving a 500 mcg tablet in 10 mL of water) four times per day, oral <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> 500 mcg per day, or a combination of the two treatments [<a href="#rid86">86</a>]. At 12 months, the Ulcer Severity Score decreased by approximately 54 percent in the betamethasone group, 46 percent in the colchicine group, and 48 percent in the combination therapy group.</p><p></p><p>Data from small observational studies suggest that the combination of <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> and <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a> may be beneficial for patients with unsatisfactory response to either agent alone [<a href="#rid41">41,87</a>]. Moreover, patients may be able to use lower doses of each of these medications, which minimizes potential side effects. (See  <a class="medical medical_review" href="/z/d/html/8239.html" rel="external">"Treatment of Behçet syndrome", section on 'Oral aphthae and genital ulcers'</a>.)</p><p class="headingAnchor" id="H3703025791"><span class="h3">Other therapies</span><span class="headingEndMark"> — </span>Therapies that have been used in patients with severe, recalcitrant RAS include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thalidomide</strong> – <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">Thalidomide</a> has been used for the treatment of severe aphthous stomatitis and the mucocutaneous lesions of Behçet syndrome (based upon its immunomodulatory properties) as well as for treatment of oral ulcers in HIV-positive patients [<a href="#rid41">41,56,88,89</a>].</p><p></p><p class="bulletIndent1">The usual dose is 50 to 100 mg daily, but 25 mg daily may be useful as a maintenance dose [<a href="#rid90">90</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">Thalidomide</a> is a known teratogen. In the United States, thalidomide can only be prescribed through a Risk Evaluation and Mitigation Strategy (REMS) program (www.thalomidrems.com), a registration and monitoring program for the safe use of thalidomide [<a href="#rid91">91</a>]. There are also concerns about the development of peripheral neuropathy, which may be irreversible.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Apremilast</strong> – <a class="drug drug_general" data-topicid="94524" href="/z/d/drug information/94524.html" rel="external">Apremilast</a> is an oral phosphodiesterase 4 (PDE4) inhibitor that inhibits production of proinflammatory cytokines and is approved for the treatment of Behçet syndrome, psoriasis, and psoriatic arthritis.</p><p></p><p class="bulletIndent1">In a small series of five patients with RAS refractory to treatment with topical corticosteroids and <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a>, <a class="drug drug_general" data-topicid="94524" href="/z/d/drug information/94524.html" rel="external">apremilast</a> at a dose of 30 mg twice daily induced a complete clearance in four of five patients and an almost complete clearance in one patient over a period of two to six weeks [<a href="#rid92">92</a>]. In another study that included 15 patients with RAS refractory to conventional therapy and not previously treated with systemic medications, treatment with apremilast 30 mg daily for 16 weeks induced a reduction in the visual analog scale pain score [<a href="#rid93">93</a>]. However, recurrence occurred after treatment discontinuation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Montelukast</strong> – <a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">Montelukast</a>, a leukotriene inhibitor, may improve pain and healing of oral ulcers when taken at a dose of 10 mg per day for one month followed by 10 mg every other day [<a href="#rid80">80</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pentoxifylline</strong> – <a class="drug drug_general" data-topicid="9757" href="/z/d/drug information/9757.html" rel="external">Pentoxifylline</a> 400 mg three times daily may have some limited benefits in aphthous stomatitis [<a href="#rid94">94</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anti-TNF-alpha agents</strong> – Anti-tumor necrosis factor (TNF)-alpha agents, including <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">etanercept</a>, <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a>, <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a>, and <a class="drug drug_general" data-topicid="9086" href="/z/d/drug information/9086.html" rel="external">golimumab</a>, have all been successfully used to treat severe and recalcitrant RAS [<a href="#rid95">95,96</a>]. In one patient series, 16 of 18 patients with RAS experienced complete or almost complete clearance of their lesions following treatment with one or more of these agents over a period of 3 to 77 months [<a href="#rid95">95</a>].</p><p></p><p class="bulletIndent1">Although potentially effective, these agents should be reserved for patients with disabling disease that has failed to respond to more conservative measures.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laser therapy </strong>– The efficacy of low-level laser therapy for the treatment of RAS has been evaluated in a few randomized trials and systematic reviews [<a href="#rid63">63-65,97-99</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A 2020 systematic review of five randomized trials that compared low-level laser therapy using different types of lasers (eg, neodymium-doped yttrium aluminum garnet [Nd:YAG] laser, aluminum gallium indium phosphide [AlGaInP] diode laser) with topical therapies (eg, <a class="drug drug_general" data-topicid="10015" href="/z/d/drug information/10015.html" rel="external">triamcinolone</a> acetonide, amlexanox) indicated that laser therapy was associated with immediate pain reduction and more rapid re-epithelization compared with topical agents [<a href="#rid99">99</a>]. However, all included studies were deemed to be at high risk of bias.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A 2023 systematic review focusing on clinical trials published in the previous five years and evaluating the efficacy of food supplements, topical treatments, and systemic treatments for RAS found acceptable evidence that laser therapy using different types of lasers (eg, Nd:YAG laser, AlGaInP diode laser) was more effective than other topical treatments in reducing pain, decreasing ulcer size, and decreasing the time to healing [<a href="#rid67">67</a>].</p><p></p><p class="headingAnchor" id="H1801415118"><span class="h2">Unproven therapies</span></p><p class="headingAnchor" id="H3054173240"><span class="h3">Vitamin supplementation</span><span class="headingEndMark"> — </span>The role of vitamin supplementation in patients with RAS remains controversial. However, appropriate supplementation should be given to patients with documented nutritional deficiency.</p><p class="bulletIndent1"><span class="glyph">●</span>One small randomized trial suggested that <a class="drug drug_general" data-topicid="9302" href="/z/d/drug information/9302.html" rel="external">vitamin B12</a> may be beneficial in all patients with RAS regardless of vitamin B12 level [<a href="#rid100">100</a>]. In this study including 58 patients with RAS treated with sublingual vitamin B12 (at a dose of 1000 mcg daily) or placebo for six months, vitamin B12 was more effective than placebo in reducing the number of RAS episodes and oral pain regardless of initial vitamin B12 levels in the blood. Moreover, after six months of treatment, 74 percent of individuals in the intervention group were free of ulceration compared with 32 percent of individuals in the control group. No adverse effects were reported in either group. (See  <a class="medical medical_review" href="/z/d/html/7154.html" rel="external">"Treatment of vitamin B12 and folate deficiencies"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a randomized trial of similar design that included 160 adults with a history of minor RAS, multivitamin supplementation for up to one year was no more effective than placebo in reducing the number and duration of RAS episodes [<a href="#rid24">24</a>]. This study was judged at a lower risk of bias compared with the one summarized above [<a href="#rid59">59</a>].</p><p></p><p class="headingAnchor" id="H2207595298"><span class="h3">Probiotics</span><span class="headingEndMark"> — </span>The role of oral or topical probiotics in the management of RAS has been evaluated in a systematic review and meta-analysis of seven randomized trials [<a href="#rid101">101</a>]. Most of the included studies did not find a beneficial effect on ulcer severity, number and size of ulcers, and healing time. However, probiotics have shown some beneficial effects in reducing pain compared with placebo [<a href="#rid102">102-105</a>].</p><p class="headingAnchor" id="H3321288140"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>The overall prognosis for patients with minor aphthosis is excellent. It is a self-limited disease that can periodically result in moderate discomfort but is otherwise well tolerated. However, in some patients with major aphthosis, the pain and frequency of outbreaks may have a significant impact on the overall quality of life. Fortunately, both forms of RAS tend to improve as patients age.</p><p class="headingAnchor" id="H1733884228"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Recurrent aphthous stomatitis (RAS) is a common disease of the oral mucosa characterized by the recurrent development of one to several discrete ulcers that typically heal within two weeks. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical subtypes</strong> – Clinical subtypes of RAS include minor aphthous stomatitis (most common), major aphthous stomatitis, herpetiform aphthous stomatitis, and severe aphthous stomatitis. Minor aphthosis is the more common form of the disease. Patients experience several self-limited episodes per year, and involvement is limited to the oral mucosa. Patients with major aphthosis may have both the oral and genital mucosa involved. The lesions are more numerous, more painful, and larger, often taking up to four to six weeks to resolve. (See <a class="local">'Clinical subtypes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation </strong>– RAS<strong> </strong>presents with round to oval, painful ulcers varying in size from a few millimeters to &gt;1 cm. Ulcers typically show an erythematous rim and adherent, yellowish exudate centrally  (<a class="graphic graphic_picture graphicRef63475 graphicRef114283 graphicRef114284" href="/z/d/graphic/63475.html" rel="external">picture 1A-C</a>). Patients with minor aphthosis have one to five discrete ulcers that are generally &lt;1 cm in diameter and most commonly develop on the nonkeratinized oral mucosa (typically buccal and labial mucosae). In most cases, lesions resolve in 10 to 14 days. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of RAS is usually made on clinical grounds, based upon a typical history and physical examination. Most patients are otherwise healthy. In patients with more severe or recalcitrant disease, it is appropriate to evaluate for underlying disease. In patients with major aphthosis, the diagnosis of Behçet syndrome must be excluded. Biopsy of a lesion will not distinguish between these two entities. (See <a class="local">'Evaluation and diagnosis'</a> above and <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – Treatment of aphthae is not always necessary, as the pain is often tolerable and does not interfere with daily life activities. When indicated or requested by patients, treatment is aimed at relieving pain, speeding up healing, and decreasing the frequency of episodes. However, there is no uniformly effective therapy for RAS. General measures aimed at oral hygiene, avoidance of trauma to the oral mucosa, and use of topical pain relievers and anti-inflammatory drugs are appropriate for all patients with RAS. (See <a class="local">'General measures for all patients'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Initial treatment</strong> – For all patients with RAS, we suggest the high-potency topical corticosteroid <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> rather than other topical agents or no treatment (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We use dexamethasone elixir 0.5 mg/5 mL to swish and spit three to four times per day. Alternatively, <a class="drug drug_general" data-topicid="9276" href="/z/d/drug information/9276.html" rel="external">clobetasol</a><strong> </strong>0.05% gel or ointment can be applied to lesions two to three times per day. (See <a class="local">'Topical corticosteroids'</a> above.)</p><p></p><p class="bulletIndent2">Other topical agents that can be used as alternatives or in combination with topical corticosteroids include <a class="drug drug_general" data-topicid="9953" href="/z/d/drug information/9953.html" rel="external">sucralfate</a> suspension, amlexanox (not available in the United States), and topical <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>. Based on limited clinical trial data, these agents appear to be safe and improve pain and ulcer healing compared with placebo. (See <a class="local">'Other topical agents'</a> above.)</p><p></p><p class="bulletIndent2">The role of oral multivitamin supplementation, including <a class="drug drug_general" data-topicid="9302" href="/z/d/drug information/9302.html" rel="external">vitamin B12</a> supplementation in patients without a documented deficiency, remains uncertain. (See <a class="local">'Vitamin supplementation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Refractory aphthosis</strong> – For patients with refractory RAS, we suggest a short course of oral corticosteroids rather than <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> or <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a> as initial therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We typically use oral <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 20 to 40 mg per day for four to seven days. In patients with major aphthosis, treatment can be prolonged until improvement of aphthae and associated symptoms is noted and then tapered down. In most patients, intermittent use of systemic corticosteroids (up to three times per year) in combination with topical corticosteroids or other topical therapies is sufficient for disease control. (See <a class="local">'Systemic corticosteroids'</a> above.)</p><p></p><p class="bulletIndent2">However, for patients with RAS who require more frequent or longer courses of systemic corticosteroids, <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> and/or <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a> can be alternative treatments. The usual starting dose of colchicine is 0.6 mg orally once daily, which can be gradually increased to 1.2 mg once daily, as tolerated. Dapsone at a starting dose of 25 to 50 mg daily may be an alternative or an adjunct to colchicine for patients who tolerate only a low dose of colchicine. (See <a class="local">'Colchicine/dapsone'</a> above.)</p><p></p><p class="bulletIndent2">Other systemic agents that have been used with some success in patients with severe, recalcitrant RAS include <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a>, <a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">montelukast</a>, <a class="drug drug_general" data-topicid="9757" href="/z/d/drug information/9757.html" rel="external">pentoxifylline</a>, <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>, and anti-tumor necrosis factor (TNF)-alpha agents. (See <a class="local">'Other therapies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – In most patients, RAS resolves or subsides spontaneously with age. In a minority of patients with major aphthosis, the pain and frequency of outbreaks may have a significant impact on the overall quality of life. (See <a class="local">'Prognosis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Edgar NR, Saleh D, Miller RA. Recurrent Aphthous Stomatitis: A Review. J Clin Aesthet Dermatol 2017; 10:26.</a></li><li><a class="nounderline abstract_t">Cui RZ, Bruce AJ, Rogers RS 3rd. Recurrent aphthous stomatitis. Clin Dermatol 2016; 34:475.</a></li><li><a class="nounderline abstract_t">Tarakji B, Gazal G, Al-Maweri SA, et al. Guideline for the diagnosis and treatment of recurrent aphthous stomatitis for dental practitioners. J Int Oral Health 2015; 7:74.</a></li><li><a class="nounderline abstract_t">Akintoye SO, Greenberg MS. Recurrent aphthous stomatitis. Dent Clin North Am 2014; 58:281.</a></li><li><a class="nounderline abstract_t">Scully C, Porter S. Oral mucosal disease: recurrent aphthous stomatitis. Br J Oral Maxillofac Surg 2008; 46:198.</a></li><li><a class="nounderline abstract_t">Chattopadhyay A, Shetty KV. Recurrent aphthous stomatitis. Otolaryngol Clin North Am 2011; 44:79.</a></li><li><a class="nounderline abstract_t">Lau CB, Smith GP. Recurrent aphthous stomatitis: A comprehensive review and recommendations on therapeutic options. Dermatol Ther 2022; 35:e15500.</a></li><li><a class="nounderline abstract_t">Chattopadhyay A, Chatterjee S. Risk indicators for recurrent aphthous ulcers among adults in the US. Community Dent Oral Epidemiol 2007; 35:152.</a></li><li><a class="nounderline abstract_t">Slebioda Z, Szponar E, Kowalska A. Etiopathogenesis of recurrent aphthous stomatitis and the role of immunologic aspects: literature review. Arch Immunol Ther Exp (Warsz) 2014; 62:205.</a></li><li><a class="nounderline abstract_t">Najafi S, Firooze Moqadam I, Mohammadzadeh M, et al. Interleukin-10 gene polymorphisms in recurrent aphthous stomatitis. Immunol Invest 2014; 43:405.</a></li><li><a class="nounderline abstract_t">Buño IJ, Huff JC, Weston WL, et al. Elevated levels of interferon gamma, tumor necrosis factor alpha, interleukins 2, 4, and 5, but not interleukin 10, are present in recurrent aphthous stomatitis. Arch Dermatol 1998; 134:827.</a></li><li><a class="nounderline abstract_t">Ozyurt K, Celik A, Sayarlıoglu M, et al. Serum Th1, Th2 and Th17 cytokine profiles and alpha-enolase levels in recurrent aphthous stomatitis. J Oral Pathol Med 2014; 43:691.</a></li><li><a class="nounderline abstract_t">Günhan Ö, Günal A, Avcı A, et al. Oral epithelial barrier function and the role of nuclear factor kappa-β pathway in the pathogenesis of aphthous ulceration. Turk J Gastroenterol 2013; 24:508.</a></li><li><a class="nounderline abstract_t">Gallo C, Barros F, Sugaya N, et al. Differential expression of toll-like receptor mRNAs in recurrent aphthous ulceration. J Oral Pathol Med 2012; 41:80.</a></li><li><a class="nounderline abstract_t">Keogan MT. Clinical Immunology Review Series: an approach to the patient with recurrent orogenital ulceration, including Behçet's syndrome. Clin Exp Immunol 2009; 156:1.</a></li><li><a class="nounderline abstract_t">Surboyo MDC, Boedi RM, Hariyani N, et al. The expression of TNF-α in recurrent aphthous stomatitis: A systematic review and meta-analysis. Cytokine 2022; 157:155946.</a></li><li><a class="nounderline abstract_t">Albanidou-Farmaki E, Deligiannidis A, Markopoulos AK, et al. HLA haplotypes in recurrent aphthous stomatitis: a mode of inheritance? Int J Immunogenet 2008; 35:427.</a></li><li><a class="nounderline abstract_t">Yousefi H, Gholami M, Zoughi M, et al. Role of genetic polymorphisms in recurrent aphthous stomatitis: A systematic review and meta-analysis. Cytokine 2022; 153:155864.</a></li><li><a class="nounderline abstract_t">Kounoupis V, Andreadis D, Georgaki M, et al. IL-10 and TGF-β1 gene polymorphisms in Greek patients with recurrent aphthous stomatitis. Med Oral Patol Oral Cir Bucal 2022; 27:e426.</a></li><li><a class="nounderline abstract_t">Marchini L, Campos MS, Silva AM, et al. Bacterial diversity in aphthous ulcers. Oral Microbiol Immunol 2007; 22:225.</a></li><li><a class="nounderline abstract_t">Kim YJ, Choi YS, Baek KJ, et al. Mucosal and salivary microbiota associated with recurrent aphthous stomatitis. BMC Microbiol 2016; 16 Suppl 1:57.</a></li><li><a class="nounderline abstract_t">Hijazi K, Lowe T, Meharg C, et al. Mucosal microbiome in patients with recurrent aphthous stomatitis. J Dent Res 2015; 94:87S.</a></li><li><a class="nounderline abstract_t">Hijazi K, Morrison RW, Mukhopadhya I, et al. Oral bacterial diversity is inversely correlated with mucosal inflammation. Oral Dis 2020; 26:1566.</a></li><li><a class="nounderline abstract_t">Lalla RV, Choquette LE, Feinn RS, et al. Multivitamin therapy for recurrent aphthous stomatitis: a randomized, double-masked, placebo-controlled trial. J Am Dent Assoc 2012; 143:370.</a></li><li><a class="nounderline abstract_t">Safari-Faramani R, Salehi M, Ghambari Haji Shore S, Omidpanah N. Serum level of vitamin D in patients with recurrent aphthous stomatitis: A systematic review and meta-analysis of case control studies. Clin Exp Dent Res 2023.</a></li><li><a class="nounderline abstract_t">Wardhana, Datau EA. Recurrent aphthous stomatitis caused by food allergy. Acta Med Indones 2010; 42:236.</a></li><li><a class="nounderline abstract_t">Scully C. Clinical practice. Aphthous ulceration. N Engl J Med 2006; 355:165.</a></li><li><a class="nounderline abstract_t">Yousefi H, Abdollahi M. An Update on Drug-induced Oral Reactions. J Pharm Pharm Sci 2018; 21:171.</a></li><li><a class="nounderline abstract_t">Bratel J, Hakeberg M. Anamnestic findings from patients with recurrent aphthous stomatitis. Swed Dent J 2014; 38:143.</a></li><li><a class="nounderline abstract_t">Sawair FA. Does smoking really protect from recurrent aphthous stomatitis? Ther Clin Risk Manag 2010; 6:573.</a></li><li><a class="nounderline abstract_t">Marakoğlu K, Sezer RE, Toker HC, Marakoğlu I. The recurrent aphthous stomatitis frequency in the smoking cessation people. Clin Oral Investig 2007; 11:149.</a></li><li><a class="nounderline abstract_t">Keenan AV, Spivakovksy S. Stress associated with onset of recurrent aphthous stomatitis. Evid Based Dent 2013; 14:25.</a></li><li><a class="nounderline abstract_t">Wray D, Graykowski EA, Notkins AL. Role of mucosal injury in initiating recurrent aphthous stomatitis. Br Med J (Clin Res Ed) 1981; 283:1569.</a></li><li><a class="nounderline abstract_t">Stenman G, Heyden G. Premonitory stages of recurrent aphthous stomatitis. I. Histological and enzyme histochemical investigations. J Oral Pathol 1980; 9:155.</a></li><li><a class="nounderline abstract_t">Baccaglini L, Lalla RV, Bruce AJ, et al. Urban legends: recurrent aphthous stomatitis. Oral Dis 2011; 17:755.</a></li><li><a class="nounderline abstract_t">Chen H, Sui Q, Chen Y, et al. Impact of haematologic deficiencies on recurrent aphthous ulceration: a meta-analysis. Br Dent J 2015; 218:E8.</a></li><li><a class="nounderline abstract_t">Başarslan F, Kaba İ. Evaluation of Vitamin D Levels in Pediatric Patients With Recurrent Aphthous Stomatitis. Cureus 2022; 14:e32064.</a></li><li><a class="nounderline abstract_t">Arduino PG, Porter SR. Oral and perioral herpes simplex virus type 1 (HSV-1) infection: review of its management. Oral Dis 2006; 12:254.</a></li><li><a class="nounderline abstract_t">Alpsoy E. Behçet's disease: A comprehensive review with a focus on epidemiology, etiology and clinical features, and management of mucocutaneous lesions. J Dermatol 2016; 43:620.</a></li><li><a class="nounderline abstract_t">Alpsoy E, Zouboulis CC, Ehrlich GE. Mucocutaneous lesions of Behcet's disease. Yonsei Med J 2007; 48:573.</a></li><li><a class="nounderline abstract_t">Letsinger JA, McCarty MA, Jorizzo JL. Complex aphthosis: a large case series with evaluation algorithm and therapeutic ladder from topicals to thalidomide. J Am Acad Dermatol 2005; 52:500.</a></li><li><a class="nounderline abstract_t">Jorizzo JL, Salisbury PL, Rogers RS 3rd, et al. Oral lesions in systemic lupus erythematosus. Do ulcerative lesions represent a necrotizing vasculitis? J Am Acad Dermatol 1992; 27:389.</a></li><li><a class="nounderline abstract_t">Ródenas JM, Ortego N, Herranz MT, et al. Cyclic neutropenia: a cause of recurrent aphthous stomatitis not to be missed. Dermatology 1992; 184:205.</a></li><li><a class="nounderline abstract_t">Ali NS, Sartori-Valinotti JC, Bruce AJ. Periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) syndrome. Clin Dermatol 2016; 34:482.</a></li><li><a class="nounderline abstract_t">Kaneko Y, Nakai N, Kida T, et al. Mouth and Genital Ulcers with Inflamed Cartilage Syndrome: Case Report and Review of the Published Work. Indian J Dermatol 2016; 61:347.</a></li><li><a class="nounderline abstract_t">Hidalgo-Tenorio C, Sabio-Sánchez JM, Linares PJ, et al. Magic syndrome and true aortic aneurysm. Clin Rheumatol 2008; 27:115.</a></li><li><a class="nounderline abstract_t">Mekinian A, Lambert M, Beregi JP, et al. Aortic aneurysm in MAGIC syndrome successfully managed with combined anti-TNF-alpha and stent grafting. Rheumatology (Oxford) 2009; 48:1169.</a></li><li><a class="nounderline abstract_t">Ng CS, Hogan P, McKenzie S, et al. Mouth and genital ulcers with inflamed cartilage (MAGIC) syndrome complicated by aneurysmal aortitis. J Clin Rheumatol 2007; 13:221.</a></li><li><a class="nounderline abstract_t">Shakeri R, Zamani F, Sotoudehmanesh R, et al. Gluten sensitivity enteropathy in patients with recurrent aphthous stomatitis. BMC Gastroenterol 2009; 9:44.</a></li><li><a class="nounderline abstract_t">Bucci P, Carile F, Sangianantoni A, et al. Oral aphthous ulcers and dental enamel defects in children with coeliac disease. Acta Paediatr 2006; 95:203.</a></li><li><a class="nounderline abstract_t">Nieri M, Tofani E, Defraia E, et al. Enamel defects and aphthous stomatitis in celiac and healthy subjects: Systematic review and meta-analysis of controlled studies. J Dent 2017; 65:1.</a></li><li><a class="nounderline abstract_t">Greuter T, Bertoldo F, Rechner R, et al. Extraintestinal Manifestations of Pediatric Inflammatory Bowel Disease: Prevalence, Presentation, and Anti-TNF Treatment. J Pediatr Gastroenterol Nutr 2017; 65:200.</a></li><li><a class="nounderline abstract_t">Field EA, Allan RB. Review article: oral ulceration--aetiopathogenesis, clinical diagnosis and management in the gastrointestinal clinic. Aliment Pharmacol Ther 2003; 18:949.</a></li><li><a class="nounderline abstract_t">Patil N, Chaurasia VR, Babaji P, et al. The effect of highly active antiretroviral therapy on the prevalence of oral manifestation in human immunodeficiency virus-infected patients in Karnataka, India. Eur J Dent 2015; 9:47.</a></li><li><a class="nounderline abstract_t">Kerr AR, Ship JA. Management strategies for HIV-associated aphthous stomatitis. Am J Clin Dermatol 2003; 4:669.</a></li><li><a class="nounderline abstract_t">Jacobson JM, Greenspan JS, Spritzler J, et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med 1997; 336:1487.</a></li><li><a class="nounderline abstract_t">van der Hilst JC, Bodar EJ, Barron KS, et al. Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome. Medicine (Baltimore) 2008; 87:301.</a></li><li><a class="nounderline abstract_t">Ranganath SP, Pai A. Is Optimal Management of Recurrent Aphthous Stomatitis Possible? A Reality Check. J Clin Diagn Res 2016; 10:ZE08.</a></li><li><a class="nounderline abstract_t">Brocklehurst P, Tickle M, Glenny AM, et al. Systemic interventions for recurrent aphthous stomatitis (mouth ulcers). Cochrane Database Syst Rev 2012; :CD005411.</a></li><li><a class="nounderline abstract_t">Spivakovsky S. Inconclusive evidence on systemic treatments for recurrent aphthous stomatitis. Evid Based Dent 2012; 13:120.</a></li><li><a class="nounderline abstract_t">Belenguer-Guallar I, Jiménez-Soriano Y, Claramunt-Lozano A. Treatment of recurrent aphthous stomatitis. A literature review. J Clin Exp Dent 2014; 6:e168.</a></li><li><a class="nounderline abstract_t">Scully C, Gorsky M, Lozada-Nur F. The diagnosis and management of recurrent aphthous stomatitis: a consensus approach. J Am Dent Assoc 2003; 134:200.</a></li><li><a class="nounderline abstract_t">Suter VGA, Sjölund S, Bornstein MM. Effect of laser on pain relief and wound healing of recurrent aphthous stomatitis: a systematic review. Lasers Med Sci 2017; 32:953.</a></li><li><a class="nounderline abstract_t">Han M, Fang H, Li QL, et al. Effectiveness of Laser Therapy in the Management of Recurrent Aphthous Stomatitis: A Systematic Review. Scientifica (Cairo) 2016; 2016:9062430.</a></li><li><a class="nounderline abstract_t">Pavlić V, vujić-Aleksić V, Aoki A, Nežić L. Treatment of recurrent aphthous stomatitis by laser therapy: A systematic review of the literature. Vojnosanit Pregl 2015; 72:722.</a></li><li><a class="nounderline abstract_t">Liu H, Tan L, Fu G, et al. Efficacy of Topical Intervention for Recurrent Aphthous Stomatitis: A Network Meta-Analysis. Medicina (Kaunas) 2022; 58.</a></li><li><a class="nounderline abstract_t">Parra-Moreno FJ, Egido-Moreno S, Schemel-Suárez M, et al. Treatment of recurrent aphtous stomatitis: A systematic review. Med Oral Patol Oral Cir Bucal 2023; 28:e87.</a></li><li><a class="nounderline abstract_t">Alli BY, Erinoso OA, Olawuyi AB. Effect of sodium lauryl sulfate on recurrent aphthous stomatitis: A systematic review. J Oral Pathol Med 2019; 48:358.</a></li><li><a class="nounderline abstract_t">Liu C, Zhou Z, Liu G, et al. Efficacy and safety of dexamethasone ointment on recurrent aphthous ulceration. Am J Med 2012; 125:292.</a></li><li><a class="nounderline abstract_t">Skulason S, Holbrook WP, Kristmundsdottir T. Clinical assessment of the effect of a matrix metalloproteinase inhibitor on aphthous ulcers. Acta Odontol Scand 2009; 67:25.</a></li><li><a class="nounderline abstract_t">Gorsky M, Epstein J, Rabenstein S, et al. Topical minocycline and tetracycline rinses in treatment of recurrent aphthous stomatitis: a randomized cross-over study. Dermatol Online J 2007; 13:1.</a></li><li><a class="nounderline abstract_t">Chugh A, Patnana AK, Kumar P, et al. The clinical efficacy of minocycline mouth rinse on recurrent aphthous stomatitis-A randomized controlled trial. Indian J Dent Res 2022; 33:24.</a></li><li><a class="nounderline abstract_t">Al-Maweri SA, Halboub E, Ashraf S, et al. Single application of topical doxycycline in management of recurrent aphthous stomatitis: a systematic review and meta-analysis of the available evidence. BMC Oral Health 2020; 20:231.</a></li><li><a class="nounderline abstract_t">Alpsoy E, Er H, Durusoy C, Yilmaz E. The use of sucralfate suspension in the treatment of oral and genital ulceration of Behçet disease: a randomized, placebo-controlled, double-blind study. Arch Dermatol 1999; 135:529.</a></li><li><a class="nounderline abstract_t">Rattan J, Schneider M, Arber N, et al. Sucralfate suspension as a treatment of recurrent aphthous stomatitis. J Intern Med 1994; 236:341.</a></li><li><a class="nounderline abstract_t">Soylu Özler G, Okuyucu Ş, Akoğlu E. The Efficacy of Sucralfate and Chlorhexidine as an Oral Rinse in Patients with Recurrent Aphthous Stomatitis. Adv Med 2014; 2014:986203.</a></li><li><a class="nounderline abstract_t">Al-Maweri SA, Alaizari N, Alanazi RH, et al. Efficacy of hyaluronic acid for recurrent aphthous stomatitis: a systematic review of clinical trials. Clin Oral Investig 2021; 25:6561.</a></li><li><a class="nounderline abstract_t">Bhat S, Sujatha D. A clinical evaluation of 5% amlexanox oral paste in the treatment of minor recurrent aphthous ulcers and comparison with the placebo paste: a randomized, vehicle controlled, parallel, single center clinical trial. Indian J Dent Res 2013; 24:593.</a></li><li><a class="nounderline abstract_t">Rodríguez M, Rubio JA, Sanchez R. Effectiveness of two oral pastes for the treatment of recurrent aphthous stomatitis. Oral Dis 2007; 13:490.</a></li><li><a class="nounderline abstract_t">Femiano F, Buonaiuto C, Gombos F, et al. Pilot study on recurrent aphthous stomatitis (RAS): a randomized placebo-controlled trial for the comparative therapeutic effects of systemic prednisone and systemic montelukast in subjects unresponsive to topical therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010; 109:402.</a></li><li><a class="nounderline abstract_t">Femiano F, Gombos F, Scully C. Recurrent aphthous stomatitis unresponsive to topical corticosteroids: a study of the comparative therapeutic effects of systemic prednisone and systemic sulodexide. Int J Dermatol 2003; 42:394.</a></li><li><a class="nounderline abstract_t">Oh J, Lee JW, Chung KB, et al. Safety, Efficacy, and Drug Survival of Colchicine in Recurrent Aphthous Stomatitis in a Real-World Setting. Ann Dermatol 2022; 34:22.</a></li><li><a class="nounderline abstract_t">Cabras M, Carrozzo M, Gambino A, et al. Value of colchicine as treatment for recurrent oral ulcers: A systematic review. J Oral Pathol Med 2020; 49:731.</a></li><li><a class="nounderline abstract_t">Davatchi F, Sadeghi Abdollahi B, Tehrani Banihashemi A, et al. Colchicine versus placebo in Behçet's disease: randomized, double-blind, controlled crossover trial. Mod Rheumatol 2009; 19:542.</a></li><li><a class="nounderline abstract_t">Sharquie KE, Najim RA, Abu-Raghif AR. Dapsone in Behçet's disease: a double-blind, placebo-controlled, cross-over study. J Dermatol 2002; 29:267.</a></li><li><a class="nounderline abstract_t">Alsahaf S, Alkurdi KA, Challacombe SJ, Tappuni AR. Topical betamethasone and systemic colchicine for treatment of recurrent aphthous stomatitis: a randomised clinical trial. BMC Oral Health 2023; 23:709.</a></li><li><a class="nounderline abstract_t">Lynde CB, Bruce AJ, Rogers RS 3rd. Successful treatment of complex aphthosis with colchicine and dapsone. Arch Dermatol 2009; 145:273.</a></li><li><a class="nounderline abstract_t">Wu JJ, Huang DB, Pang KR, et al. Thalidomide: dermatological indications, mechanisms of action and side-effects. Br J Dermatol 2005; 153:254.</a></li><li><a class="nounderline abstract_t">Hello M, Barbarot S, Bastuji-Garin S, et al. Use of thalidomide for severe recurrent aphthous stomatitis: a multicenter cohort analysis. Medicine (Baltimore) 2010; 89:176.</a></li><li><a class="nounderline abstract_t">Deng Y, Wei W, Wang Y, et al. A Randomized controlled clinical trial on dose optimization of thalidomide in maintenance treatment for recurrent aphthous stomatitis. J Oral Pathol Med 2022; 51:106.</a></li><li class="breakAll">US Food and Drug Administration. Thalomid (thalidomide) risk evaluation and mitigation strategy; Summit, NJ: Celgene Corporation; September 2014. www.fda.gov/downloads/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm222649.pdf (Accessed on August 09, 2017).</li><li><a class="nounderline abstract_t">Kolios AGA, Yawalkar N, Feusi A, et al. Apremilast in Treatment-Refractory Recurrent Aphthous Stomatitis. N Engl J Med 2019; 381:1975.</a></li><li><a class="nounderline abstract_t">Pincelli T, Butendieck RR Jr, Heckman MG, et al. Apremilast for severe recurrent aphthous stomatitis: A prospective pilot study. J Am Acad Dermatol 2023; 88:459.</a></li><li><a class="nounderline abstract_t">Thornhill MH, Baccaglini L, Theaker E, Pemberton MN. A randomized, double-blind, placebo-controlled trial of pentoxifylline for the treatment of recurrent aphthous stomatitis. Arch Dermatol 2007; 143:463.</a></li><li><a class="nounderline abstract_t">Sand FL, Thomsen SF. Efficacy and safety of TNF-α inhibitors in refractory primary complex aphthosis: a patient series and overview of the literature. J Dermatolog Treat 2013; 24:444.</a></li><li><a class="nounderline abstract_t">O'Neill ID, Scully C. Biologics in oral medicine: ulcerative disorders. Oral Dis 2013; 19:37.</a></li><li><a class="nounderline abstract_t">Yilmaz HG, Albaba MR, Caygur A, et al. Treatment of recurrent aphthous stomatitis with Er,Cr:YSGG laser irradiation: A randomized controlled split mouth clinical study. J Photochem Photobiol B 2017; 170:1.</a></li><li><a class="nounderline abstract_t">Alidaee MR, Taheri A, Mansoori P, Ghodsi SZ. Silver nitrate cautery in aphthous stomatitis: a randomized controlled trial. Br J Dermatol 2005; 153:521.</a></li><li><a class="nounderline abstract_t">Khaleel Ahmed M, Jafer M, Nayeem M, et al. Low-Level Laser Therapy and Topical Medications for Treating Aphthous Ulcers: A Systematic Review. J Multidiscip Healthc 2020; 13:1595.</a></li><li><a class="nounderline abstract_t">Volkov I, Rudoy I, Freud T, et al. Effectiveness of vitamin B12 in treating recurrent aphthous stomatitis: a randomized, double-blind, placebo-controlled trial. J Am Board Fam Med 2009; 22:9.</a></li><li><a class="nounderline abstract_t">Cheng B, Zeng X, Liu S, et al. The efficacy of probiotics in management of recurrent aphthous stomatitis: a systematic review and meta-analysis. Sci Rep 2020; 10:21181.</a></li><li><a class="nounderline abstract_t">Dugourd PM, Martin H, Fontas E, et al. Probiotics for recurrent idiopathic aphthous stomatitis in adults: a placebo-controlled randomized trial. J Eur Acad Dermatol Venereol 2020; 34:e239.</a></li><li><a class="nounderline abstract_t">Pedersen AML, Bukkehave KH, Bennett EP, Twetman S. Effect of Lozenges Containing Lactobacillus reuteri on the Severity of Recurrent Aphthous Ulcers: a Pilot Study. Probiotics Antimicrob Proteins 2020; 12:819.</a></li><li><a class="nounderline abstract_t">Aggour RL, Mahmoud SH, Abdelwhab A. Evaluation of the effect of probiotic lozenges in the treatment of recurrent aphthous stomatitis: a randomized, controlled clinical trial. Clin Oral Investig 2021; 25:2151.</a></li><li><a class="nounderline abstract_t">Mimura MAM, Borra RC, Hirata CHW, de Oliveira Penido N. Immune response of patients with recurrent aphthous stomatitis challenged with a symbiotic. J Oral Pathol Med 2017; 46:821.</a></li></ol></div><div id="topicVersionRevision">Topic 112654 Version 14.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28360966" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Recurrent Aphthous Stomatitis: A Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27343962" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Recurrent aphthous stomatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26028911" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Guideline for the diagnosis and treatment of recurrent aphthous stomatitis for dental practitioners.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24655523" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Recurrent aphthous stomatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17850936" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Oral mucosal disease: recurrent aphthous stomatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21093624" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Recurrent aphthous stomatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35395126" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Recurrent aphthous stomatitis: A comprehensive review and recommendations on therapeutic options.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17331156" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Risk indicators for recurrent aphthous ulcers among adults in the US.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24217985" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Etiopathogenesis of recurrent aphthous stomatitis and the role of immunologic aspects: literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24564196" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Interleukin-10 gene polymorphisms in recurrent aphthous stomatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9681346" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Elevated levels of interferon gamma, tumor necrosis factor alpha, interleukins 2, 4, and 5, but not interleukin 10, are present in recurrent aphthous stomatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24801453" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Serum Th1, Th2 and Th17 cytokine profiles and alpha-enolase levels in recurrent aphthous stomatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24623290" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Oral epithelial barrier function and the role of nuclear factor kappa-βpathway in the pathogenesis of aphthous ulceration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21554403" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Differential expression of toll-like receptor mRNAs in recurrent aphthous ulceration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19210521" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Clinical Immunology Review Series: an approach to the patient with recurrent orogenital ulceration, including Behçet's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35728503" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The expression of TNF-αin recurrent aphthous stomatitis: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19046300" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : HLA haplotypes in recurrent aphthous stomatitis: a mode of inheritance?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35313259" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Role of genetic polymorphisms in recurrent aphthous stomatitis: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35660731" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : IL-10 and TGF-β1 gene polymorphisms in Greek patients with recurrent aphthous stomatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17600533" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Bacterial diversity in aphthous ulcers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27036492" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Mucosal and salivary microbiota associated with recurrent aphthous stomatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25540188" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Mucosal microbiome in patients with recurrent aphthous stomatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32419230" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Oral bacterial diversity is inversely correlated with mucosal inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22467697" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Multivitamin therapy for recurrent aphthous stomatitis: a randomized, double-masked, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37786385" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Serum level of vitamin D in patients with recurrent aphthous stomatitis: A systematic review and meta-analysis of case control studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21063045" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Recurrent aphthous stomatitis caused by food allergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16837680" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Clinical practice. Aphthous ulceration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29789102" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : An Update on Drug-induced Oral Reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25796808" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Anamnestic findings from patients with recurrent aphthous stomatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21151626" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Does smoking really protect from recurrent aphthous stomatitis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17273857" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The recurrent aphthous stomatitis frequency in the smoking cessation people.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23579306" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Stress associated with onset of recurrent aphthous stomatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6796169" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Role of mucosal injury in initiating recurrent aphthous stomatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6776249" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Premonitory stages of recurrent aphthous stomatitis. I. Histological and enzyme histochemical investigations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21812866" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Urban legends: recurrent aphthous stomatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25720915" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Impact of haematologic deficiencies on recurrent aphthous ulceration: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36600845" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Evaluation of Vitamin D Levels in Pediatric Patients With Recurrent Aphthous Stomatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16700734" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Oral and perioral herpes simplex virus type 1 (HSV-1) infection: review of its management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27075942" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Behçet's disease: A comprehensive review with a focus on epidemiology, etiology and clinical features, and management of mucocutaneous lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17722228" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Mucocutaneous lesions of Behcet's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15761429" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Complex aphthosis: a large case series with evaluation algorithm and therapeutic ladder from topicals to thalidomide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1401272" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Oral lesions in systemic lupus erythematosus. Do ulcerative lesions represent a necrotizing vasculitis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1392113" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Cyclic neutropenia: a cause of recurrent aphthous stomatitis not to be missed.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27343963" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27293269" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Mouth and Genital Ulcers with Inflamed Cartilage Syndrome: Case Report and Review of the Published Work.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17657547" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Magic syndrome and true aortic aneurysm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19549787" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Aortic aneurysm in MAGIC syndrome successfully managed with combined anti-TNF-alpha and stent grafting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17762460" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Mouth and genital ulcers with inflamed cartilage (MAGIC) syndrome complicated by aneurysmal aortitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19534771" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Gluten sensitivity enteropathy in patients with recurrent aphthous stomatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16449028" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Oral aphthous ulcers and dental enamel defects in children with coeliac disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28688949" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Enamel defects and aphthous stomatitis in celiac and healthy subjects: Systematic review and meta-analysis of controlled studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27801751" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Extraintestinal Manifestations of Pediatric Inflammatory Bowel Disease: Prevalence, Presentation, and Anti-TNF Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14616160" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Review article: oral ulceration--aetiopathogenesis, clinical diagnosis and management in the gastrointestinal clinic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25713484" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : The effect of highly active antiretroviral therapy on the prevalence of oral manifestation in human immunodeficiency virus-infected patients in Karnataka, India.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14507229" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Management strategies for HIV-associated aphthous stomatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9154767" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19011501" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27891490" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Is Optimal Management of Recurrent Aphthous Stomatitis Possible? A Reality Check.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22972085" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Systemic interventions for recurrent aphthous stomatitis (mouth ulcers).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23258184" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Inconclusive evidence on systemic treatments for recurrent aphthous stomatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24790718" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Treatment of recurrent aphthous stomatitis. A literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12636124" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : The diagnosis and management of recurrent aphthous stomatitis: a consensus approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28345122" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Effect of laser on pain relief and wound healing of recurrent aphthous stomatitis: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28078164" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Effectiveness of Laser Therapy in the Management of Recurrent Aphthous Stomatitis: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26495699" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Treatment of recurrent aphthous stomatitis by laser therapy: A systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35744034" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Efficacy of Topical Intervention for Recurrent Aphthous Stomatitis: A Network Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36173717" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Treatment of recurrent aphtous stomatitis: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30839136" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Effect of sodium lauryl sulfate on recurrent aphthous stomatitis: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22340928" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Efficacy and safety of dexamethasone ointment on recurrent aphthous ulceration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18991147" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Clinical assessment of the effect of a matrix metalloproteinase inhibitor on aphthous ulcers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17498420" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Topical minocycline and tetracycline rinses in treatment of recurrent aphthous stomatitis: a randomized cross-over study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35946240" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : The clinical efficacy of minocycline mouth rinse on recurrent aphthous stomatitis-A randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32831085" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Single application of topical doxycycline in management of recurrent aphthous stomatitis: a systematic review and meta-analysis of the available evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10328192" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : The use of sucralfate suspension in the treatment of oral and genital ulceration of Behçet disease: a randomized, placebo-controlled, double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8077892" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Sucralfate suspension as a treatment of recurrent aphthous stomatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26556433" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : The Efficacy of Sucralfate and Chlorhexidine as an Oral Rinse in Patients with Recurrent Aphthous Stomatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34542725" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Efficacy of hyaluronic acid for recurrent aphthous stomatitis: a systematic review of clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24355961" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : A clinical evaluation of 5% amlexanox oral paste in the treatment of minor recurrent aphthous ulcers and comparison with the placebo paste: a randomized, vehicle controlled, parallel, single center clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17714352" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Effectiveness of two oral pastes for the treatment of recurrent aphthous stomatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19926502" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Pilot study on recurrent aphthous stomatitis (RAS): a randomized placebo-controlled trial for the comparative therapeutic effects of systemic prednisone and systemic montelukast in subjects unresponsive to topical therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12755982" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Recurrent aphthous stomatitis unresponsive to topical corticosteroids: a study of the comparative therapeutic effects of systemic prednisone and systemic sulodexide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35221591" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Safety, Efficacy, and Drug Survival of Colchicine in Recurrent Aphthous Stomatitis in a Real-World Setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32281694" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Value of colchicine as treatment for recurrent oral ulcers: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19597921" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Colchicine versus placebo in Behçet's disease: randomized, double-blind, controlled crossover trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12081158" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Dapsone in Behçet's disease: a double-blind, placebo-controlled, cross-over study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37789351" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Topical betamethasone and systemic colchicine for treatment of recurrent aphthous stomatitis: a randomised clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19289756" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Successful treatment of complex aphthosis with colchicine and dapsone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16086735" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Thalidomide: dermatological indications, mechanisms of action and side-effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20453604" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Use of thalidomide for severe recurrent aphthous stomatitis: a multicenter cohort analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34773292" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : A Randomized controlled clinical trial on dose optimization of thalidomide in maintenance treatment for recurrent aphthous stomatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34773292" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : A Randomized controlled clinical trial on dose optimization of thalidomide in maintenance treatment for recurrent aphthous stomatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31722161" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Apremilast in Treatment-Refractory Recurrent Aphthous Stomatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35709978" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Apremilast for severe recurrent aphthous stomatitis: A prospective pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17438178" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : A randomized, double-blind, placebo-controlled trial of pentoxifylline for the treatment of recurrent aphthous stomatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23621315" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Efficacy and safety of TNF-αinhibitors in refractory primary complex aphthosis: a patient series and overview of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22471882" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Biologics in oral medicine: ulcerative disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28359996" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Treatment of recurrent aphthous stomatitis with Er,Cr:YSGG laser irradiation: A randomized controlled split mouth clinical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16120136" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Silver nitrate cautery in aphthous stomatitis: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33239881" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Low-Level Laser Therapy and Topical Medications for Treating Aphthous Ulcers: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19124628" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Effectiveness of vitamin B12 in treating recurrent aphthous stomatitis: a randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33273680" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : The efficacy of probiotics in management of recurrent aphthous stomatitis: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31954066" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Probiotics for recurrent idiopathic aphthous stomatitis in adults: a placebo-controlled randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31410765" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Effect of Lozenges Containing Lactobacillus reuteri on the Severity of Recurrent Aphthous Ulcers: a Pilot Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32820431" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Evaluation of the effect of probiotic lozenges in the treatment of recurrent aphthous stomatitis: a randomized, controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28776757" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Immune response of patients with recurrent aphthous stomatitis challenged with a symbiotic.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
